Funding newsPublished October 15, 2026

Crystalys Therapeutics Raises $130.0M Series B

Recently funded · $130.0M Series bHospitals and Health CareUSView source

Get the full Crystalys Therapeutics company profile

Access contacts, investors, buying signals & more

Crystalys Therapeutics has raised $130.0M in Series B funding to push its gout treatment into late-stage global trials.

The clinical-stage biopharmaceutical company is developing dotinurad, a next-generation URAT1 inhibitor it describes as having best-in-class potential for safety and efficacy. The drug is headed into global Phase 3 trials as a second-line therapy for gout, backed by clinical data from approvals in multiple Asian markets. Crystalys was co-founded by Novo Holdings and Catalys Pacific.

From the source

Butch

Orion Talent Salute To The "Leader-Doers" + "Movers & Shakers" At The Following Biopharma Organizations - Success Is Never An Accident - Let's Continue To Put The CARE In Healthcare! Two-Way Communication Is Critical. Communicate, Connect, AND Collaborate.

Upfront Caring & Upfront Meticulous Attention To Detail Yields "Mutuality" & "Priority-Clarity-Alignment" + Strong Back End Performance~ No Successful Relationship Or Partnership Was Ever Successfully Sustained Off One Sided Concessions - Let's Continue To Work TOGETHER As Industry Partners To Put PATIENTS FIRST!! EVERY SECOND COUNTS!!! CURES MATTER (The Result)!!!! BUT THE PROPER PROCESS MATTE

Unlock the full source

CEO quotes, investor details and growth metrics

Start free trial

Other United States companies recently funded

View all

Leaven Foods
A 2026 NEXTY Award winner for “Best Pantry Staple” at the prestigious Natural Products Expo, Leaven’s "Instant Sourdough" is the first and only real sourdough starter replacement that eliminates the need for a traditional sourdough starter for commercial and home bakers. Made from carefully curated wild yeast and beneficial bacteria isolated from sourdough, it delivers real sourdough fermentation, flavor and benefits in a convenient powdered format. Bakers simply mix it into the dough; allow it to rise, ferment, and then bake. No starter required. In addition, Leaven offers an Instant Wild Yeast, a premium baking yeast for better baking performance. It’s an undomesticated wild yeast that delivers a rich, buttery flavor creating delicious bread the way it's meant to taste. Both products are all natural, non-GMO and gluten-free. Founded by microbiologists with a passion for baking, Leaven Foods, harnesses the microbial power of ancient fermentations to create all-natural, flavorful, healthier, and more sustainable food. At the heart of Leaven Foods is a proprietary fermentation platform designed to understand and preserve the complex microbial ecosystems that make wild fermentation so unique. With 1/3 of food fermented, the mission is bigger than sourdough. Leaven will bring the complexity, flavor and potential benefits of naturally fermented foods to the masses. Leaven is building a new generation of fermentation ingredients and applications, starting with sourdough and expanding into other baked goods and fermented foods. By combining microbiology, computational biology and food science, Leaven is making wild fermentation more accessible, convenient and scalable, without compromising what makes it special.
$2.0M Seed

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#	Company	Round	Amount	Date
1	Shockwave Medical United States	Unknown	$13.1B	2y ago
2	NeuroEM Therapeutics United States	Unknown

Other recent Series b rounds

Companies that recently closed a Series b round.

#	Company	Round	Amount	Date
1	North United States	Series b	$60.0M	today
2	Sava Nutrition	Series b	$36.0M	today
3